Advancing through Genomics Appendix Company Profile Company Structure

  • Slides: 21
Download presentation

Advancing through Genomics

Advancing through Genomics

Appendix Company Profile Company Structure Organization Chart CEO BOD Auditors Advisory Board Life Science

Appendix Company Profile Company Structure Organization Chart CEO BOD Auditors Advisory Board Life Science Research Center Employees: 101 Research Staff: 79 Ph. D. : 12 Advisory Board: 10 Bioinformatics Research Center Management Div. Corporate Planning Div. Biochip Division Mouse Division Genomics Division Employee/ R&D BS, P&L Statement Nuclear Transfer team Phenotype Anal. team Knockout team Transgenic team Microinjection team R&D team WGS team Sequencing team Domestic Sales team Overseas Sales team Bioinformatics team R&D team Product dev. team Domestic Sales team

Pathfinder in Genome Research Strategy Pioneer in Genome Research Corporate Profile Infancy Ø Founded

Pathfinder in Genome Research Strategy Pioneer in Genome Research Corporate Profile Infancy Ø Founded in June, 1997 q Began as ILCHUN Molecular Medicine Institute at Seoul N. U in 1987 q Wealth of experience ü Molecular biology ü Computer science ü Transgenic Mouse ü Knockout mouse ü Nuclear Transfer technology ü Cloning Growth Mature Ø IPO in February, 2000 ØNet Sales of 10 M$ in 2004 Ø Korean BAC Genome Project in June, 2001 q Constructed 100 K BAC library q The first bio-venture listed in Kosdaq q Funded $40 million q Bought 10 ABI 3700 DNA Analyzers & 4 ABI 3730 DNA Analyzers q Set the Gene Array Systems q Automated all the prep. procedures q Completed a whole microbe genome - Zymomonas Mobilis (2001) q Successfully cloned mouse (2001) q Obtained 1, 500 disease related BAC libraries q Expanding mouse facility q Pushed into the Japanese Market by the marketing alliance with As. One, Inc. q Mongolian Genome Project with Seoul National Univ. and the ministry of health of Mongolia, for the help of MOST(Korean gov. ) Corporate Identity

Pathfinder in Genome Research Strategy Business Strategy Focus Corporate Profile Corporate Identity Genome Information

Pathfinder in Genome Research Strategy Business Strategy Focus Corporate Profile Corporate Identity Genome Information Microarray BAC diagnosis Model Organism Bioinformatics The Service Provider on Genome Research Information-based Drug & Diagnosis

R&D and Service & Product 1. 시퀀싱 서비스 R&D Automation: Colony Picking(Q-Bot) → DNA

R&D and Service & Product 1. 시퀀싱 서비스 R&D Automation: Colony Picking(Q-Bot) → DNA Prep. (Tecan/MWG) → PCR(PE/AP/MJ) → ABI 3700, ABI 3730→ Track Record: Bioinformatics Zymomonas mobilis Korean Genome BAC end sequencing Xanthomonas oryzae Leuconostoc mesenderoides Corynebacterium ammomigenes Various Sequencing Service 품목 Primer Extension Sequencing 1060 Clients in over 150 cities, about 50 countries Shotgun Sequencing BAC End. Sequencing Use Macrogen’s Gene Sequencing Analysis Service. 고객수, 분포 등 Avr. Readlength 850 bp 48 hrs of world-wide delivery Cosmid Sequencing Primer Walk Sequencing Core competency

R&D and Service 2. DNA 칩 사업부 Service & Product R&D DNA Chip Expression-Profiling

R&D and Service 2. DNA 칩 사업부 Service & Product R&D DNA Chip Expression-Profiling DNA Chip - Human Oligo 10 K, Mouse Oligo 11 K Disease Monitoring DNA Chip - Breast Cancer / Chemotherapy / Radiation Bioinformatics Fragment Assembly Service Text Mining SNP Detection Genome Annotation Core competency

R&D and Service & Product 3. 마우스 사업부 R&D Core competency Applications of Mouse

R&D and Service & Product 3. 마우스 사업부 R&D Core competency Applications of Mouse cloning technology to the Knockout and Xenotransplantation

R&D and Service 4. Xenotransplantation Service & Product R&D Core competency From Therapeutic Proteins

R&D and Service 4. Xenotransplantation Service & Product R&D Core competency From Therapeutic Proteins to Xenotransplatation Production of nuclear transfer-derived swine that express the enhanced green fluorescent protein. (Anim Biotech 2001; 12: 173 -181. ) Production of (1, 3) Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning (Science, 2002 ; 295: 1089 -1092)

Vision & Strategy Vision Statement Systematic Research Base Core Technology Ø Genome Research Ø

Vision & Strategy Vision Statement Systematic Research Base Core Technology Ø Genome Research Ø In Situ Ø Gene Screening Ø In Silico Ø Target Validation Ø In Vivo q Sequencing Korean genome q Expression Chip - Human 10 K, Mouse 11 K - Whole Genome 30 K q Transgenic Mouse q Disease model mouse q 100 K BAC library - Obtained 1, 500 diseased related BACs q Disease Monitoring Chips - Breast Cancer - Chemotherapy - Radiation q Completely sequenced the entire Zymomoas Mobilis q Diagnostic Chip - Genomic DNA Chip - Analysis System q sequenced whole genome of several microbes q Bioinformatics - Fragment Assembly Service - Text Mining - SNP Detection - Genome Annotation q Sequencing Entire Korean c. DNA q Knockout Mouse q Cloning R&D Strategy Future Product

Vision & Strategy Vision Statement Genomics Drugs Core Technology R&D Strategy Knockout and Pharmacogenomics

Vision & Strategy Vision Statement Genomics Drugs Core Technology R&D Strategy Knockout and Pharmacogenomics with Genomics-based Drugs Future Product

When BT meets IT,

When BT meets IT,

인간 게놈 프로젝트: Bio. Digital Convergence의 기원 Venter and Collins bury their differences for

인간 게놈 프로젝트: Bio. Digital Convergence의 기원 Venter and Collins bury their differences for the joint announcement of the draft map -2000. 6. 26

Genomic Information

Genomic Information

Paradigm Shift: BT는 정보과학이다.

Paradigm Shift: BT는 정보과학이다.

바이오디지털 혁명 “We have barely begun to feel the convergence. ” 엘빈 토플러 impact

바이오디지털 혁명 “We have barely begun to feel the convergence. ” 엘빈 토플러 impact of the biodigital “To imagine that the new economy is over is the equivalent of thinking, in the early 1800 s, that the industrial revolution was over because textile manufactures were going broke in Manchester. ” The obvious, inescapable fact is that the revolution is real, and it manifests itself at many levels simultaneously. 『 New Economy? You Ain't Seen Nothin' Yet 』 2001. 3. 29, The Wall Street Journal - By Alvin and Heidi Toffl